Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3667632 | 0.70 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL11589267 | 0.67 | KMT2A (0.43) | ALDH1A1TSHR | |
| SCHEMBL13864108 | 0.66 | TSHR (0.41) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL7778354 | 0.66 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL28419918 | 0.66 | SMPD1 (0.37) | TSHR | |
| SCHEMBL14473467 | 0.65 | ALDH1A1 (0.38) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL14473469 | 0.65 | ALDH1A1 (0.39) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL16395877 | 0.65 | ALDH1A1 (0.34) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL7719309 | 0.64 | — | — | |
| SCHEMBL8927959 | 0.64 | ALDH1A1 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | ImMutriX Therapeutics, Inc. (US) | 2025-05-13 | — | — | US | claimed |
| EP-3298129-B1 | METHOD OF PREPARING UNIVERSAL BLOOD PRODUCT | IMMUTRIX THERAPEUTICS INC (US) | 2024-05-01 | — | — | EP | claimed |
| US-20220152524-A1 | UNIVERSAL BLOOD PRODUCT AND METHODS OF PREPARING AND USING SAME | PROPRIETARY TECHNOLOGY ASSETS, LLC (US) | 2022-05-19 | — | — | US | claimed |
| US-11253794-B2 | Universal blood product and methods of preparing and using same | PROPRIETARY TECHNOLOGY ASSETS, LLC (US) | 2022-02-22 | — | — | US | claimed |
| CN-111741783-A | In vitro devices and methods for treating complement factor-associated diseases | 甘布罗伦迪亚股份公司 | 2020-10-02 | — | — | CN | claimed |
| EP-1518870-B1 | SEPARATING MATERIAL | GAMBRO LUNDIA AB (SE) | 2018-11-28 | — | — | EP | claimed |
| US-9844621-B2 | Separation material | GAMBRO LUNDIA AB (SE) | 2017-12-19 | — | — | US | claimed |
| EP-2741796-A1 | SEPARATION MATERIAL | Gambro Lundia AB (SE) | 2014-06-18 | — | — | EP | claimed |
| EP-2741795-A1 | SEPARATION MATERIAL COMPRISING SACCHARIDE LIGANDS | Gambro Lundia AB (SE) | 2014-06-18 | — | — | EP | claimed |
| EP-2261271-B1 | SEPARATION MATERIAL | GAMBRO LUNDIA AB (SE) | 2014-04-30 | — | — | EP | claimed |
| WO-2013020964-A1 | SEPARATION MATERIAL COMPRISING SACCHARIDE LIGANDS | GAMBRO LUNDIA AB (SE) | 2013-02-14 | — | — | WO | claimed |
| WO-2013020967-A1 | SEPARATION MATERIAL | GAMBRO LUNDIA AB (SE) | 2013-02-14 | — | — | WO | claimed |
| US-20120160771-A1 | Separation Material | GAMBRO LUNDIA AB (SE) | 2012-06-28 | — | — | US | claimed |
| US-8142844-B2 | Separating material | GAMBRO LUNDIA AB (SE) | 2012-03-27 | — | — | US | claimed |
| EP-2261271-A1 | Separation material | Gambro Lundia AB (SE) | 2010-12-15 | — | — | EP | claimed |
| US-20060264355-A1 | Separating material | GAMBRO LUNDIA AB | 2006-11-23 | — | — | US | claimed |
| EP-1518870-A1 | Separating material | Gambro Lundia AB (SE) | 2005-03-30 | — | — | EP | claimed |
| WO-2005026224-A1 | SEPARATING MATERIAL | GAMBRO LUNDIA AB (SE) | 2005-03-24 | — | — | WO | claimed |
| EP-4744693-A1 | BLOOD TREATMENT DEVICE COMPRISING ALKALINE PHOSPHATASE | Gambro Lundia AB (SE) | 2026-05-20 | — | — | EP | disclosed |
| WO-1996022316-A1 | POLYMERISABLE DERIVATIVES OF POLYAMIDES | MERCK PATENT GMBH (DE) | 1996-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220152524-A1 | UNIVERSAL BLOOD PRODUCT AND METHODS OF PREPARING AND USING SAME | HLA-C, HBG1, HBB | ALDH1A1 2090/4885TRPC6 4793/4885TSHR 4099/4885 |
| US-20060264355-A1 | Separating material | ILK, PCNA, HLA-B | ALDH1A1 308/4885TRPC6 3656/4885TSHR 4880/4885 |
| US-11253794-B2 | Universal blood product and methods of preparing and using same | HBG1, CD44, HBB | ALDH1A1 1984/4885TRPC6 4810/4885TSHR 4023/4885 |
| US-12296085-B2 | Method for extracorporeal treatment of preeclampsia and related disorders | TEK, FLT4, PGF | ALDH1A1 4553/4885TRPC6 4330/4885TSHR 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.